Skip to content
doc.socialdoc.social

Listening

Episode

Morning Brief — Monday, November 16, 2026

Play episode— Morning Brief — Monday, November 16, 2026

Keeps playing through doc social Morning Brief

4 stories this morning, for surgeons and the people who support them.

  • Spine J (Case Western/University Hospitals, online Nov 12): among 1,618 orthopaedic surgeons and neurosurgeons billing Medicare FFS index spine operations in both 2013 and 2023, the fusion-predominant share rose from 40.9% to 52.7% (376 crossed in, 184 crossed out); real per-case reimbursement fell across all index codes and fusion paid ~1.5x decompression by 2023; surgeons who increased fusion share had a median 26.0% reduction vs 53.0% among those who did not; each 10-point within-surgeon fusion-share rise associated with a 5.5-point smaller decline; exploratory projection 73.6% fusion-predominant by 2040 — Dinesh et al., 'Practice Migration Toward Fusion-Predominant Spine Surgery', Spine J 2026 Nov 12, doi:10.1016/j.spinee.2026.11.001 (PMID 43020290). Retrospective longitudinal cohort of CMS Medicare Physician and Other Practitioners files; association only. Conversion-factor context from the CY2027 PFS final rule covered 2026-11-05. Source
  • Bracco and Avicenna.AI announce FDA 510(k) clearance of UPTUNITY | Aneurysm (CINA-Aneurysm K262062, detection; CINA-Aneurysm+ K262147, management): CADe/CADx concurrent reading aid flagging suspected saccular brain aneurysms >3 mm on head CTA with presence, location and size, plus MIMPS follow-up measurement and comparison across exams; Avicenna.AI leads US promotion and distribution; first product in Bracco's UPTUNITY AI portfolio from a partnership announced March 2026; showcased at RSNA Nov 29-Dec 3; no performance figures in the release. Competitive context: Viz.ai's Viz Aneurysm received 510(k) clearance in February 2022 — Milan, Nov 13, 2026 release. Viz Aneurysm clearance: https://www.viz.ai/news/viz-ai-receives-fda-510-k-clearance-for-viz-aneurysm (Feb 24, 2022). Source
  • Centinel Spine's prodisc L lumbar total disc replacement receives EU MDR certification (Nov 12), following MDR certification of prodisc C Vivo and C Nova announced September 2025; prodisc L in international clinical use since 1990; US two-level prodisc L approval April 2020 — West Chester, Pa., Nov 12, 2026 release. US two-level approval: https://www.biospace.com/centinel-spine-announces-fda-approval-for-two-level-prodisc-l-total-disc-replacement (April 2020). Centinel's public NYSE IPO filing was covered 2026-10-08; MDR transition deadline for class III implantables is Dec 31, 2027 under Regulation (EU) 2023/607. Source
  • J Arthroplasty, AOANJRR (online Nov 12): lifetime revision risk of primary TKA for osteoarthritis (2000-2020) by 5-year age band is highest at 46-50 (39.0%; men 41.7%, women 37.0%), falling to 0% at 96-100; morbid obesity associated with higher lifetime risk until age 80; ASA 4 highest until 65; infection had the highest cause-specific lifetime revision risk at all ages — Rele et al., 'Patient Profile and Cause-Specific Lifetime Revision Risk of Primary Total Knee Arthroplasty: An Australian Orthopaedic Association National Joint Replacement Registry Study', J Arthroplasty 2026 Nov 12, doi:10.1016/j.arth.2026.11.041 (PMID 43020157). Source

Contribute to the Brief

Faculty can send the show a note — a reaction to a paper, a correction, a read on a rule change — either written, which we shape for broadcast and read in the show's voice, or as a voice note under three minutes, which airs in your own voice. Send one from Studio.

Not on doc social yet? Contribute a lecture or join the network — doc social is a clinical education platform for clinicians, and this show is one part of it.

Narration is synthesized. Reporting and editorial judgement are ours, and every story above links to its source.